- Home
- IRON vs CBT Comparison
IRON vs CBT Comparison
Compare IRON & CBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- CBT
- Stock Information
- Founded
- IRON 2017
- CBT 2019
- Country
- IRON United States
- CBT United States
- Employees
- IRON N/A
- CBT N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- CBT Major Chemicals
- Sector
- IRON Health Care
- CBT Industrials
- Exchange
- IRON Nasdaq
- CBT Nasdaq
- Market Cap
- IRON 3.4B
- CBT 4.0B
- IPO Year
- IRON N/A
- CBT N/A
- Fundamental
- Price
- IRON $89.84
- CBT $59.51
- Analyst Decision
- IRON Strong Buy
- CBT Hold
- Analyst Count
- IRON 12
- CBT 3
- Target Price
- IRON $108.83
- CBT $74.00
- AVG Volume (30 Days)
- IRON 531.4K
- CBT 485.6K
- Earning Date
- IRON 11-06-2025
- CBT 11-03-2025
- Dividend Yield
- IRON N/A
- CBT 3.03%
- EPS Growth
- IRON N/A
- CBT N/A
- EPS
- IRON N/A
- CBT 6.02
- Revenue
- IRON N/A
- CBT $3,713,000,000.00
- Revenue This Year
- IRON N/A
- CBT $6.09
- Revenue Next Year
- IRON N/A
- CBT $3.05
- P/E Ratio
- IRON N/A
- CBT $9.88
- Revenue Growth
- IRON N/A
- CBT N/A
- 52 Week Low
- IRON $30.82
- CBT $58.99
- 52 Week High
- IRON $95.95
- CBT $115.16
- Technical
- Relative Strength Index (RSI)
- IRON 64.84
- CBT 24.96
- Support Level
- IRON $83.00
- CBT $60.03
- Resistance Level
- IRON $90.39
- CBT $62.57
- Average True Range (ATR)
- IRON 3.70
- CBT 2.03
- MACD
- IRON -0.40
- CBT -0.12
- Stochastic Oscillator
- IRON 74.77
- CBT 4.72
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About CBT Cabot Corporation
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.